Valneva SE: Setback with One Vaccine and Success News with Another!
If VLA15 is approved in 2026, a fundamental reassessment situation could develop!
Valneva could become an acquisition target for a large pharmaceutical company like Pfizer!
Reading Time: 1 minute
Among European biotechs, Valneva SE (i.) has been making headlines since July with its strength. The company has a diverse portfolio and already has approved vaccines for Chikungunya, Cholera, and Japanese Encephalitis (JE). Additionally, they are researching vaccines for Shigella, Zika, and Lyme disease. Following a recent setback with the Chikungunya vaccine in the USA, the stock caught investors' attention again on September 3rd. The trigger was the release of positive Phase 2 data for the Lyme disease vaccine candidate VLA15. The results showed...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
